Trial Profile

Clinical Effectiveness of Egg-derived Polyclonal Antibodies (IM-01) for the Treatment of Mild-moderate Clostridium Difficile Infection (CDI)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IM 01 (Primary)
Indications Clostridium difficile infections
Focus Therapeutic Use
Acronyms IM-01
Sponsors ImmuniMed

Most Recent Events

14 Dec 2022 Planned number of patients changed from 72 to 60.
14 Dec 2022 Planned End Date changed from 1 Jan 2022 to 30 Mar 2024.
14 Dec 2022 Planned primary completion date changed from 30 Sep 2020 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com